Get App
Download App Scanner
Scan to Download
Advertisement
This Article is From Feb 01, 2022

Sun Pharma, HPCL, Oberoi Realty, Ajanta Pharma & More Q3 Reviews: HDFC Securities

Sun Pharma, HPCL, Oberoi Realty, Ajanta Pharma & More Q3 Reviews: HDFC Securities

Sun Pharma, HPCL, Oberoi Realty, Ajanta Pharma & More Q3 Reviews: HDFC Securities
Stock figures are displayed on screens.  (Photographer: Kiyoshi Ota/Bloomberg)

BQ Blue's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BloombergQuint's subscribers an opportunity to expand their understanding of companies, sectors and the economy.

HDFC Securities Institutional Equities

Sun Pharmaceutical Industries Ltd. - Sun Pharma's Q3 revenue/Ebitda came in line with our estimates, led by growth across businesses. Its global specialty business grew 17% QoQ to $183 million on the back of decent ramp-up in Ilumya, Cequa, Levulan, and Absorica.

Hindustan Petroleum Corporation Ltd. - Our optimism for HPCL is premised on 1. recovery in domestic demand for petroleum products in FY22/23, 2. improvement in refining margins over the coming 18 months, and 3. sustainability of auto fuel gross margin over Rs 4.5/litre.

Oberoi Realty Ltd. - Oberoi Realty registered the highest ever quarterly presales of 1.04 million square feet (2.4 times/2.0 times QoQ/YoY) for a booking value of Rs 19.6 billion (2.4 times/2.0 times QoQ/YoY) due to strong demand across all projects.

Ajanta Pharma Ltd. - While Ajanta Pharma's Q3 revenue/Ebitda came in ~3% below our estimates, primarily due to weak performance in the U.S. and Asia markets, profit after tax came ~10% ahead of our estimates, buoyed by lower-than-expected taxes. Ebitda margin, at 28.6%, was broadly in line.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search
Add NDTV Profit As Google Preferred Source